Company intelligence / Profile preview

Breakthrough Diagnostics

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

Breakthrough Diagnostics, Inc. developed the LymPro Test™, a blood-based diagnostic assessing cell cycle dysfunction in peripheral lymphocytes for early detection of Alzheimer’s disease. The test showed statistically significant correlation with amyloid PET imaging (r = -0.849; p = 0.00000216) in published data from July 2019. The company also aimed to create blood tests for early detection of cancer and other neurodegenerative disorders, leveraging peripheral blood analysis to uncover biochemical changes associated with disease[1][2].

Therapeutic areas: OncologyNeurology
Modalities: Diagnostic DeviceBlood Test
Industry: Molecular Diagnostics

Partnerships

Amarantus Bioscience HoldingsLeipzig University

Beyond the preview

Go deeper on Breakthrough Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Breakthrough Diagnostics.

Explore the full profile